- Reaction score
- 224
Thanks. Yes, I think these concentrations are in the ballpark where we want to be with such a topical regimen. 1mcg/mL (0.0001%) would give concentrations around 100nM (1000 times the EC50 value of 0.1nM, order of magnitude). I think 10mcg/mL (0.001%) is too much, since the concentration will then be closer to 1uM. Experimenting with WAY can probably give similiar results (since the scalp hardly has ER-alpha expression anyway), however I think it is redundant because E2 in such low quantities will not give systemic sides anyway, and it is way (no pun intended) more expensive and harder to source than plain E2. I am also still not sure if WAY is a full agonist of the ER-beta, which is a requirement to be effective. I have never seen evidence that this is the case, which makes me sceptical. For an AA, RU is absolutely inferior to Apalutamide or Darolutamide. I recently switched to Darolutamide (because the half-life is more favorable than Apalutamide) and it is really only needed at 0.1% (that may be overkill as well). Add in Finasteride or Dutasteride and the whole balding cascade has essentially been shut down. I really like how everything works in tandem:Unfortunately there is only the abstract available of the article that tested balding scalp derived DP cells, but it seems, with the limit of the in vitro model, the cells response break point happen at a lower concentration: >36 nM, so maybe 2X , so 72 nM?
The full text study says cell proliferation was increased starting from 180 nM and the study on hair shaft elongation model in vitro says 100 nM is suitable (even not optimal like the 10 nM).
I would go for a compromise concentration of 200 nM, that should be realized by a topical at 0.001 % order of magnitude, but you can make the math with your model based with the vehicle you have selected. Even assuming a full scalp application, namely 2 ml, the total estradiol would be 0.02 mg, that I don't think it's enough to cause unwanted sides.
I'm going to run a similar test with WAY-200070 and RU (just because I don't have a better AA in my hands now).
-Finasteride/Dutasteride removes the most potent androgen (DHT), which increases the efficiacy of the AA.
-Darolutamide/Apalutamide blocks the AR, will cause AR upregulation.
-E2 directly counteracts AR upregulation.
I added Cyclosporine A (at 0.1%) because the extensive research I ran on it points at a reasonable safety profile at such topical concentrations. Cyclo addresses many problems of the balding cascade: in addition to stimulation the Wnt pathway by inhibiting sFRP-1, it also provides direct suppression of interleukins which are further down the chain (they are produced as a reaction of an androgen binding de AR in a "male pattern baldness-sensitive" follicle). So, it is both a growth stimulant through Wnt as well as a preventive agent through inhibiting IL's. Some people are running WAY-316606 instead, but that compound only inhibits sFRP-1 (and does nothing to counteract IL's).
I am still torn on Minoxidil (sulfate). It is very effective as a growth simulant, but it gives me horrible skin texture. Currently I am not using it and not really planning on using it again. If you can run it without any bothersome sides I would definitely include it in the topical formulation. Another bonus of the topical is that all drugs are FDA-approved: long term effects are all known and safety warnings have been published where applicable. I still recommend anyone who wishes to try this to research everything you are going to use extensively. FDA approved does not necessarily mean safe or without side effects.
Last edited: